Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

The most underrated software feature I've encountered recently is automated scheduling based on completion date. Many apps ...

I, however, just wanted to get my firewood off the porch, where it was overly sheltered for anything but fully dried wood, ...

Joplin doesn’t chase trends. No AI noise, no bloated features. It quietly does the job of being a reliable second brain, and ...